Merck Study Results Confirm Potential Of Atacicept As Candidate Therapy For SLE

VIENNA dpaAFX Merck KGaA MKGAY.PK reported the results of the ADDRESS II Phase IIb multicenter study on atacicept in patients with systemic lupus erythematosus. The company said although ...
Read the full story: Bioportfolio Latest News